Industry Willing To Let US FDA Go Slowly With Real-Time Review Expansion

 
• By Derrick Gingery

Program growth beyond supplements will be determined after the agency gains experience with STAR program, PhRMA executive tells the Pink Sheet.

FDA building
Postmarket negotiations during application assessments are expected to improve by starting earlier.

More from User Fees

More from Pathways & Standards